Eun-Gee Park

Eun-Gee Park

Auto-generated profile, based on publicly available information

Eun-Gee Park

Korea Institute of Drug Safety & Risk Management Anyang Republic of Korea

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2021 in Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
JBJae Hyun Bae
Jae Hyun Bae
EPEun-Gee Park
Eun-Gee Park
SKSunhee Kim
Sunhee Kim
SKSin Gon Kim
Sin Gon Kim
SHSeokyung Hahn
Seokyung Hahn
NKNam Hoon Kim
Nam Hoon Kim
Background: To compare the renal effects of dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors on individual outcomes in patients with type 2 diabetes.Methods: We searched electronic databases (MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials) from inception to June 2019 to identity eligible randomized controlled trials of DPP-4 inhibitors or SGLT2 inhibitors that reported at least one kidney outcome in patients with type 2 diabetes. Outcomes of interest were microalbuminuria, macroalbuminuria, worsening nephropathy, and end-stage kidney disease (ESKD). We performed an arm-based network meta-analysis using Bayesian methods and calculated absolute risks and rank probabilities of each treatment for the outcomes.Results: Seventeen studies with 87,263 patients were included. SGLT2 inhibitors significantly lowered the risks of individual kidney outcomes, including microalbuminuria (odds ratio [OR], 0.64; 95% credible interval [CrI], 0.41 to 0.93), macroalbuminuria (OR, 0.48; 95% CrI, 0.24 to 0.72), worsening nephropathy (OR, 0.65; 95% CrI, 0.44 to 0.91), and ESKD (OR, 0.65; 95% CrI, 0.46 to 0.98) as compared with placebo. However, DPP-4 inhibitors did not lower the risks. SGLT2 inhibitors were considerably associated with higher absolute risk reductions in all kidney outcomes than DPP-4 inhibitors, although the benefits were statistically insignificant. The rank probabilities showed that SGLT2 inhibitors were better treatments for lowering the risk of albuminuria and ESKD than placebo or DPP-4 inhibitors.Conclusion: SGLT2 inhibitors were superior to DPP-4 inhibitors in reducing the risk of albuminuria and ESKD in patients with type 2 diabetes.

31 January 2025 in Healthcare Informatics Research
Verified
Journal Article
Open access
PDF file
EPEun-Gee Park
Eun-Gee Park
MKMin Jung Kim
Min Jung Kim
JKJinseo Kim
Jinseo Kim
KSKichul Shin
Kichul Shin
BRBorim Ryu
Borim Ryu
Objectives: We aimed to derive observational research evidence on treatment patterns through a scoping review of common data model (CDM)-based publications. Methods: We searched the medical literature databases PubMed and EMBASE, as well as the Observational Health Data Sciences and Informatics (OHDSI) website, for papers published between January 1, 2010 and August 21, 2023 to identify research papers relevant to our topic. Results: Eighteen articles satisfied the inclusion criteria for this scoping review. We summarized study characteristics such as phenotypes, patient numbers, data periods, countries, Observational Medical Outcomes Partnership (OMOP) CDM databases, and definitions of index date and target cohort. Type 2 diabetes mellitus emerged as the most frequently studied disease, covered in five articles, followed by hypertension and depression, each addressed in four articles. Biguanides, with metformin as the primary drug, were the most commonly prescribed first-line treatments for type 2 diabetes mellitus. Most studies utilized sunburst plots to visualize treatment patterns, whereas two studies used Sankey plots. Various software tools were employed for treatment pattern analysis, including JavaScript, the open-source ATLAS by OHDSI, R code, and the R package “TreatmentPatterns.” Conclusions: This study provides a comprehensive overview of research on treatment patterns using the CDM, highlighting the growing importance of OMOP CDM in enabling multinational observational network studies and advancing collaborative research in this field.

1 January 2024 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
MKMin Jung Kim
Min Jung Kim
BRBorim Ryu
Borim Ryu
EPEun-Gee Park
Eun-Gee Park
SYSiyeon Yi
Siyeon Yi
KWANGSOO KIMKWANGSOO KIM
KWANGSOO KIM
KSKichul Shin
Kichul Shin
Kim MJ, et al. J Korean Med Sci. 2024 Jan;39(4):e37. https://doi.org/10.3346/jkms.2024.39.e37

23 August 2026 in Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
HLHaeyoung Lee
Haeyoung Lee
EPEun‐Gee Park
Eun‐Gee Park
HYHyeon-Jong Yang
Hyeon-Jong Yang
YSYoung-Gyun Seo
Young-Gyun Seo
DKDong Yoon Kang
Dong Yoon Kang
SSSoo Jung Sohn
Soo Jung Sohn
In July 2025, the Food and Drug Administration (FDA) warned of significant weight loss among young children receiving stimulants for attention‐deficit hyperactivity disorder. However, real‐world evidence on the magnitude and prevalence of stimulant‐associated weight loss remains limited. This study evaluated short‐term weight changes after methylphenidate initiation among youth aged 3–18 years using the Medical record Observation and Assessment of drug safety Common Data Model (MOA CDM) in Korea. We conducted a retrospective study using electronic health record‐based MOA CDM data from January 2008 to December 2024. The cohort included individuals aged 3–18 years with at least one methylphenidate prescription and had available weight measurements. The index date was defined as the first prescription date. Individuals without weight data within 45 days before or 90 days after the index date were excluded. Outcomes included changes in body weight (kg) and weight percentile, and the proportion having a ≥ 10‐percentile decline. Weight percentiles were calculated using the 2017 Korean National Growth Charts for Children and Adolescents. A total of 2087 youths from 17 nationwide hospitals were included; 68.71% were male, and 58.12% were aged 6–10 years. Within 3 months, mean body weight decreased by −0.33 kg (95% confidence interval [CI], −0.44 to −0.22) and mean weight percentile decreased by −2.49 percentiles (95% CI, −2.83 to −2.15). Overall, 21.57% had a ≥ 10 percentile decline, with larger reductions among pre‐school‐aged children (28.57%). Our findings underscores the importance of growth monitoring during treatment initiation.